Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Sells $695,093.46 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Patricia Carr sold 4,813 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the transaction, the chief accounting officer now directly owns 8,237 shares of the company’s stock, valued at approximately $1,189,587.54. The trade was a 36.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Jazz Pharmaceuticals Stock Up 0.9 %

Shares of JAZZ opened at $140.23 on Thursday. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $8.52 billion, a price-to-earnings ratio of 19.75, a PEG ratio of 1.04 and a beta of 0.56. The stock’s 50-day moving average price is $127.64 and its 200-day moving average price is $119.71.

Institutional Trading of Jazz Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. CWA Asset Management Group LLC purchased a new stake in shares of Jazz Pharmaceuticals in the third quarter worth about $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after buying an additional 100,112 shares during the last quarter. Centre Asset Management LLC purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth about $9,335,000. Moloney Securities Asset Management LLC purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth about $464,000. Finally, Pacer Advisors Inc. boosted its stake in shares of Jazz Pharmaceuticals by 15.3% in the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after buying an additional 278,465 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on JAZZ shares. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Robert W. Baird upped their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. JPMorgan Chase & Co. upped their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their target price for the company from $140.00 to $150.00 in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $182.47.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.